4.1 Review

Proteomic analysis of multiple myeloma: Current status and future perspectives

期刊

PROTEOMICS CLINICAL APPLICATIONS
卷 5, 期 1-2, 页码 30-37

出版社

WILEY-BLACKWELL
DOI: 10.1002/prca.201000044

关键词

Biomarkers; MS; Multiple myeloma; Proteomics; PTM

资金

  1. Chinese Academy of Sciences
  2. National Protein Research Fund [2009CB825400, 2006CB910902]
  3. Ministry of Health of China [2008ZX10003-005, 2009ZX10004-107]
  4. Slate Key Development Program for Basic Research of China [2010CB529205]
  5. Program for New Century Excellent Talents in University [NCET-09-551]

向作者/读者索取更多资源

Multiple myeloma (MM) is a malignant plasma cell neoplasm that accounts for slightly more than 10% of all hematologic cancers and remains incurable. The major challenge remains the identification of better diagnosis and prognostic biomarkers. The advent of proteomic technologies creates new opportunities and challenges for those seeking to gain greater understanding of MM. Although there is a limited number of proteomic studies to date in MM, those performed highlight the potential impact of these technologies in our understanding of MM pathogenesis and the identification of novel therapeutic targets. In this review, we introduce the proteomic technologies available for the study of MM, summarize results of the published proteomic studies on MM, and discuss the novel developments and applications for the analysis of protein PTM in MM. The application of proteomic technologies will be valuable to better understand the pathogenesis of MM and may in the future open novel avenues in the treatment of MM.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.1
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据